ReviewMagyar onkologia2025
[Modern treatment of lung cancer with immunotherapy].
Review in Magyar onkologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the case of non-small cell lung cancer, systemic treatment plays a key role in early, locally advanced as well as metastatic stages. The neoadjuvant approach is represented by the combination of immunotherapy+chemotherapy, while targeted therapy does not yet have an evidence-based place in this indication. Immune checkpoint inhibitor treatment has an important role in clinical practice in adjuvant setting as well. Several trials have also concluded with positive results regarding perioperative immunotherapy. Currently, the role of the multidisciplinary tumor board in the personalized decision-making process is essential. In locally advanced cases, immunotherapy after radiochemotherapy is also evidence-based. In advanced, non oncogene-addicted non-small cell lung cancer, the place of immunotherapy is well defined, both as monotherapy and in combination with chemotherapy. Progress has also been made in small cell lung cancer, both in extensive and limited stages, with immune checkpoint inhibitor treatment.
Indexed as
Identifiers
41385767PMC12701785What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.